<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02287519</url>
  </required_header>
  <id_info>
    <org_study_id>14-368</org_study_id>
    <nct_id>NCT02287519</nct_id>
  </id_info>
  <brief_title>Sexual Therapy and Rehabilitation After Treatment for Ovarian Cancer (START-OC): A Pilot Intervention</brief_title>
  <acronym>START-OC</acronym>
  <official_title>Sexual Therapy and Rehabilitation After Treatment for Ovarian Cancer (START-OC): A Pilot Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Patty Brisben Foundation For Women's Sexual Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is evaluating an educational intervention for women who have experienced
      changes in sexual function after treatment for ovarian cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this research is to study the effectiveness of an educational intervention for
      women who have experienced changes in sexual function after treatment for ovarian cancer. The
      aim is to develop an effective intervention to help women manage these changes and restore
      sexual health and functioning. This study consists of attending a group educational session
      followed by a one-on-one telephone counseling session.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in sexual dysfunction will be assessed by change on the Female Sexual Function Index (FSFI).</measure>
    <time_frame>Baseline, 2 month Post Intervention, 6 Month Post Intervention</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in sexual self-efficacy will be assessed by change on the Sexual Self-Efficacy Scale</measure>
    <time_frame>Baseline, 2 Month Post Intervention, 6 Month Post Intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in sexual knowledge will be assessed by change on the Sexual Knowledge after Ovarian Cancer questionnaire</measure>
    <time_frame>Baseline, 2 Month Post Intervention, 6 Month Post Intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in psychological distress will be assessed by change on the BSI-18 (Brief Symptom Inventory)</measure>
    <time_frame>Baseline, 2 Month Post Intervention, 6 Month Post Intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility of conducting a group sexual health intervention via webinar format will be assessed with descriptive data and qualitative feedback from participants</measure>
    <time_frame>Baseline, 2 Month Post Intervention, 6 Month Post Intervention</time_frame>
    <description>To explore and describe women's experience of webinar platform.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Support Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One group educational session will include information on resources, self-help strategies, and relaxation techniques.
One telephone coaching session after the group session Or
Pilot webinar format of the educational session</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Group Session</intervention_name>
    <arm_group_label>Support Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Telephone Coaching Session</intervention_name>
    <arm_group_label>Support Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Webinar</intervention_name>
    <arm_group_label>Support Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women diagnosed with Stage1-IV ovarian cancer

          -  Prognosis of at least one year to live (as assessed by provider)

          -  Endorsement of at least one sexual symptom (see Appendix A for eligibility screening)

          -  English speaking

          -  Signed informed consent

        Exclusion Criteria:

          -  History of pelvic radiation

          -  Cognitive impairment which would interfere with the ability to participate in the
             study (as assessed by provider)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharon Bober, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2014</study_first_submitted>
  <study_first_submitted_qc>November 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2014</study_first_posted>
  <last_update_submitted>November 21, 2017</last_update_submitted>
  <last_update_submitted_qc>November 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Sharon Bober, Ph.D</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

